Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
144.32(c) 144.55(c) 143.93(c) 145.08(c) 145.24(c) Last
7 250 755 5 326 540 5 221 348 5 280 253 4 090 799 Volume
-2.55% +0.16% -0.43% +0.80% +0.11% Change
More quotes
Financials (USD)
Sales 2020 81 779 M - -
Net income 2020 15 967 M - -
Net Debt 2020 6 543 M - -
P/E ratio 2020 23,9x
Yield 2020 2,74%
Sales 2021 88 232 M - -
Net income 2021 19 447 M - -
Net cash position 2021 2 007 M - -
P/E ratio 2021 19,3x
Yield 2021 2,92%
Capitalization 382 B 382 B -
EV / Sales 2020 4,76x
EV / Sales 2021 4,31x
Nbr of Employees 132 200
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... 
Sector
Pharmaceuticals
Calendar
11/11 | 11:45amPresentation
More about the company
Notations Surperformance© of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
All news about JOHNSON & JOHNSON
10/23AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
RE
10/23JOHNSON & JOHNSON : Pivotal Study of J&J's Covid-19 Vaccine to Resume, Company S..
DJ
10/23JOHNSON & JOHNSON : Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COV..
PU
10/23JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
10/23ASTRAZENECA : Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resumin..
DJ
10/22JOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2020
PR
10/22Covid-19 Vaccine Makers to Face Challenges When Recognizing Revenue
DJ
10/20JOHNSON & JOHNSON : Janssen Demonstrates Strong Commitment to Research and Devel..
AQ
10/19Correction to Stocks That Defined the Week Article on Oct. 16
DJ
10/19JOHNSON & JOHNSON : Janssen demonstrates strong commitment to research and devel..
PU
10/19JOHNSON & JOHNSON : Janssen Receives CHMP Positive Opinion for Expanded Use of T..
AQ
10/19JOHNSON & JOHNSON : to Participate in the Credit Suisse 29th Annual Virtual Heal..
AQ
10/19Eva Walde strengthens Senzime's Board of Directors
AQ
10/16STARBUCKS, JOHNSON & JOHNSON, TWITTE : Stocks That Defined the Week
DJ
10/16JOHNSON & JOHNSON : - New First-in-Class Phase 3 Data Demonstrate TREMFYA Mainta..
AQ
More news
News in other languages on JOHNSON & JOHNSON
10/23COVID-19 : le Canada annonce un accord pour un vaccin canadien
10/22LA MINUTE DURABLE : Ce trio français champion sur le climat
10/21US-WAHL/BIDEN : Korruptionsvorwürfe sind Verleumdungskampagne
10/20WDH/Moderna-Chef macht Hoffnung auf US-Notfallzulassung für Corona-Impfung
10/15VACCIN CONTRE LE COVID-19 : trop vite, trop haut, trop fort?
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 164,54 $
Last Close Price 145,24 $
Spread / Highest target 23,9%
Spread / Average Target 13,3%
Spread / Lowest Target -4,30%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.33%280 343
PFIZER INC.-2.55%207 994
MERCK & CO., INC.-12.23%200 341
NOVARTIS AG-16.62%186 175
NOVO NORDISK A/S14.86%164 146